# Vericel Corp: Form 10-Q for the period ended Jun 30, 2011

- Company: [Vericel Corp](/companies/vcel.md) (CIK 887359)
- Form: 10-Q
- Filed: 2011-08-15
- Accepted by EDGAR: Aug 15, 2011, 16:06 ET
- Period: 2011-06-30
- Accession: 0001104659-11-046981
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/887359/000110465911046981/a11-18411_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/887359/000110465911046981/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 6 months, 2011-01-01 to 2011-06-30 | $9.0k | us-gaap:SalesRevenueNet |
| Cost of revenue | 6 months, 2011-01-01 to 2011-06-30 | $2.0k | us-gaap:CostOfGoodsSold |
| Research and development | 3 months, 2011-04-01 to 2011-06-30 | $5.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2011-01-01 to 2011-06-30 | $9.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2011-04-01 to 2011-06-30 | $2.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2011-01-01 to 2011-06-30 | $4.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2011-04-01 to 2011-06-30 | −$7.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2011-01-01 to 2011-06-30 | −$13.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2011-04-01 to 2011-06-30 | $2.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2011-01-01 to 2011-06-30 | $4.0k | us-gaap:InterestExpense |
| Diluted EPS | 3 months, 2011-04-01 to 2011-06-30 | −$0.26 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2011-01-01 to 2011-06-30 | −$0.39 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months, 2011-04-01 to 2011-06-30 | 38,622,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2011-01-01 to 2011-06-30 | 38,619,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2011-01-01 to 2011-06-30 | −$12.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2011-01-01 to 2011-06-30 | $412.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2011-06-30 | $18.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-06-30 | $19.0m | us-gaap:AssetsCurrent |
| Total assets | at 2011-06-30 | $20.3m | us-gaap:Assets |
| Current liabilities | at 2011-06-30 | $30.4m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2011-06-30 | $43.0k | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2011-06-30 | $103.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2011-06-30 | −$10.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 29,556 characters.

### Overview

We are developing patient-specific, expanded multicellular therapies for use in the treatment of severe, chronic ischemic cardiovascular diseases. We believe ixmyelocel-T (the new generic name approved in March 2011 for our cardiovascular cell therapy approved in March 2011) is a disease modifying therapy with multi-functional properties including: tissue remodeling, immuno-modulation and the promotion of angiogenesis, which is targeted to address the multiple underlying causes of many severe, chronic cardiovascular diseases such as critical limb ischemia (CLI). Our proprietary cell-manufacturing technology enables the manufacture of cell therapies expanded from a patient’s own bone marrow and delivered directly to damaged tissues. Preclinical and clinical data suggest that ixmyelocel-T may be effective in treating patients with severe, chronic ischemic cardiovascular diseases such as CLI. Preliminary data utilizing ixmyelocel-T in dilated cardiomyopathy (DCM) have provided indications of efficacy and safety. Nearly 200 patients have been treated in recent clinical trials using ixmyelocel-T (over 400 patients safely treated since our inception) with no treatment related serious adverse events.

### Our Therapy

Ixmyelocel-T is a patient specific, expanded multicellular therapy developed using our proprietary, automated processing system to produce human cell products for clinical use. The Aastrom process enhances bone marrow mononuclear cells by expanding the mesenchymal stromal cells and alternatively activated macrophages while retaining many of the hematopoietic cells. The manufacture of our patient specific, expanded multicellular therapies is done under current Good Manufacturing Practices (cGMP) and current Good Tissue Practices (cGTP) guidelines required by the U.S. Food and Drug Administration (FDA).

Our therapy has several features that we believe are critical for success in treating patients with severe, chronic cardiovascular diseases:

*Patient specific (autologous) —* we start with the patient’s own cells, which are accepted by the patient’s immune system allowing the cells integrate into existing functional tissues. This characteristic of our therapy, we believe, eliminates both the risk of rejection and the risk of having to use immunosuppressive therapy pre- or post-therapy. Our data also suggests that ixmyelocel-T provides the potential for long-term engraftment and repair.

*Expanded —* we begin with a small amount of bone marrow from a patient (approximately 50 ml) and significantly expand the number of certain cell types, primarily CD90+ mesenchymal cells, CD14+ monocytes and alternatively activated macrophages to far more than are present in the patient’s own bone marrow (up to 200 times the number of these cells compared with the starting bone marrow aspirate).

*Multicellular —* we believe the multiple cell types in ixmyelocel-T, which are normally only found in bone marrow but in different quantities, possess the necessary functions required for tissue remodeling, immuno-modulation and the promotion of angiogenesis.

*Minimally invasive —* our procedure for taking bone marrow (an “aspirate”) can be performed in an out-patient setting and takes approximately 15 minutes. For diseases such as CLI, the administration of ixmyelocel-T is performed in an out-patient setting in a one-time, approximately 20 minute procedure.

*Safe —* bone marrow and bone marrow-like therapies have been used safely and efficaciously in medicine for over three decades. Our product, ixmyelocel-T, a bone marrow-derived, patient specific, expanded multicellular therapy leverages this body of scientific study and medical experience.

Our therapy is produced at our cell manufacturing facility in the United States, located at our headquarters in Ann Arbor, Michigan.

### Clinical Development Programs

Our clinical development programs are focused on addressing areas of high unmet medical needs in severe, chronic ischemic cardiovascular diseases. We have completed our Phase 2b clinical trial in CLI and expect to advance into a Phase 3 clinical trial in the fourth quarter of 2011. Our CLI development program has received Fast Track Designation from the FDA. Our DCM program is in early Phase 2 clinical development and is focused on achieving proof of concept in this indication. Our DCM development program has received Orphan Disease Designation from the FDA.

Results to date in our clinical trials may not be indicative of results obtained from subsequent patients enrolled in those trials or from future clinical trials. Further, our future clinical trials may not be successful or we may not be able to obtain the required Biologic License Application (BLA) approval to commercialize our products in the United States in a timely fashion, or at all. See “Risk Factors” in Item 1A of our Transition Report on Form 10-KT for the six month period ended December 31, 2010.

### Critical Limb Ischemia

#### Background

CLI is the most serious and advanced stage of peripheral arterial disease (PAD). PAD is a chronic atherosclerotic disease that progressively restricts blood flow in the limbs and can lead to serious medical complications. This disease is often associated with other clinical conditions including hypertension, cardiovascular disease, hyperlipidemia, diabetes, obesity and stroke. CLI is used to describe patients with the most severe forms of PAD: those with chronic ischemia-induced pain (even at rest) or tissue loss (ulcers or gangrene) in the limbs, often leading to amputation and death. CLI leads to more than 160,000 amputations per year. The one-year and four-year mortality rates for no-option CLI patients that progress to amputation are approximately 25% and 70%, respectively. Ixmyelocel-T, our disease modifying therapy with multiple functions, has shown significant promise in the treatment of CLI.

#### Clinical Programs

Our U.S. Phase 2b RESTORE-CLI program was a multi-center, randomized, double-blind, placebo controlled clinical trial. This clinical trial was designed to evaluate the safety and efficacy of ixmyelocel-T in the treatment of patients with CLI. It was the largest multi-center, randomized, double-blind, placebo-controlled cellular therapy study ever conducted in CLI patients. We completed enrollment of this trial in February 2010 with a total of 86 patients at 18 sites across the United States, with the last patient treated in March 2010. These patients were followed for a period of 12 months after treatment. In addition to assessing the safety of our product, efficacy endpoints included time to first occurrence of treatment failure — the trial’s primary end-point — (defined as major amputation, all-cause mortality, doubling in wound size and de novo gangrene), amputation-free survival (defined as major amputation and all-cause mortality), major amputation rates, level of amputation, wound healing, patient quality of life and pain scores. The primary purpose of the trial was to assess performance of our therapy and, if positive, prepare for a Phase 3 program.

Results to date of the RESTORE-CLI trial have included two planned interim analyses and a final top-line report:

- In June 2010, we reported results at the Society of Vascular Surgery Meeting. This interim analysis included the six-month results for the first 46 patients enrolled in the trial. Results of this analysis demonstrated that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure. The results related to the primary endpoint were statistically significant (p=0.0053). Analysis of the data for amputation free survival, a secondary efficacy endpoint which the study was not powered to demonstrate, showed a statistically significant reduction in event rates in favor of our therapy (p=0.038). Other endpoints measured (e.g., major amputation rate, complete wound healing, change in Wagner wound scale) showed encouraging trends, but had not reached statistical significance at the interim analysis.
- In November 2010, we presented six-month data on all 86 patients enrolled in the trial at the VEITHsymposium™ non-CME satellite session. Results of this analysis showed that the study again achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure. The findings related to time to first occurrence of treatment failure were statistically significant (p=0.0132). Further analyses showed a clinically meaningful reduction of 56% in treatment failure events. Analysis of the data for amputation-free survival, showed a clinically meaningful reduction in event rates of 24%, but did not show statistical significance (p=0.5541).
- In June 2011, we announced 12-month, top-line results from all 86 patients enrolled in the trial. Results of this analysis showed that the trial met its final primary safety and efficacy endpoints, demonstrating a statistically significant improvement in the time to first occurrence of treatment failure at 12 months. We plan to present the full data from the RESTORE-CLI trial at an appropriate medical meeting in the fourth quarter of 2011.

We continue to make progress towards the Phase 3 clinical development program in CLI — called REVIVE. In October 2010, we announced that the FDA had granted Fast Track Designation for the use of ixmyelocel-T for the CLI indication. The Fast Track program is designed to facilitate the development and expedite the review of new drugs and biologics, intended to treat serious or life-threatening conditions that demonstrate the potential to address unmet medical needs. During discussions with the FDA in June 2010, Aastrom was encouraged to use the Special Protocol Assessment (SPA) process for the Phase 3 program. In October 2010, we submitted two SPA requests to the FDA, one for the “no option” CLI patient population and another for the “poor option” CLI patient population. The primary SPA - the No-Option CLI SPA - focuses on patients that have exhausted all other treatment options with the exception of amputation. We reached agreement with the FDA on the No-Option CLI SPA in July 2011. The secondary SPA - the Poor-Option CLI SPA - focuses on patients that have not yet exhausted all other treatment options; however the options available are associated with poor outcomes.

### Dilated Cardiomyopathy

#### Background

DCM is a severe, chronic cardiovascular disease that leads to enlargement of the heart, reducing the pumping function of the heart to the point that blood circulation is impaired. Patients with DCM typically present with symptoms of congestive heart failure, including limitations in physical activity and shortness of breath. There are two types of DCM: ischemic and non-ischemic. Ischemic DCM, the most common form, is associated with atherosclerotic cardiovascular disease. Among other causes, non-ischemic DCM can be triggered by toxin exposure, virus or genetic diseases. Patient prognosis depends on the stage and cause of the disease but is typically characterized by a high mortality rate. Other than heart transplantation or ventricular assist devices, there are currently no effective treatment options for end-stage patients with this disease. According to the book, *Heart Failure: A Combined Medical and Surgical Approach* (2007), DCM affects 200,000-400,000 patients in the United States alone.

In February 2007, the FDA granted Orphan Drug Designation to our investigational therapy for the treatment of DCM. Our DCM development program is currently in Phase 2 and we have two ongoing U.S. Phase 2 trials investigating surgical and catheter-based delivery for our product in the treatment of DCM.

#### Surgical Trial Program — DCM

In May 2008, the FDA activated our investigational new drug application (IND) for surgical delivery of our therapy. The 40-patient U.S. IMPACT-DCM clinical trial began with the treatment of the first patient in November 2008. This multi-center, randomized, controlled, prospective, open-label, Phase 2 study was designed to include 20 patients with ischemic DCM and 20 patients with non-ischemic DCM. We completed enrollment of the 40 patients in the IMPACT-DCM clinical trial in January 2010 and the final patient was treated in March 2010. Participants in the IMPACT-DCM clinical trial were required to have New York Heart Association (NYHA) functional class III or IV heart failure, a left ventricular ejection fraction (LVEF) of less than or equal to 30% (60-75% is typical for a healthy person), and meet other eligibility criteria, including optimized medical therapy. Patients were randomized in an approximate 3:1 ratio of treatment to control group. Patients in the treatment group received our therapy through direct injection into the heart muscle during minimally invasive-surgery (involving a chest incision of approximately 2 inches). The primary objective of this study is to assess the safety of ixmyelocel-T in patients with DCM. Efficacy measures include cardiac dimensions and tissue mass, cardiac function (e.g. cardiac output, LVEF, cardiopulmonary exercise testing parameters), cardiac perfusion and viability, as well as other efficacy endpoints. NYHA functional class and quality of life are also assessed. Patients were followed for 12 months post-treatment.

Six-month data from the IMPACT-DCM interim analysis were presented at The Sixth International Conference on Cell Therapy for Cardiovascular Disease on January 20, 2011. Results indicated that ixmyelocel-T is safe and showed that serious adverse events were associated with the surgical procedure and not the cellular therapy. Adverse events after the initial peri-operative period were roughly equal between the control and treatment groups. Efficacy findings include positive trends in quality of life and functional and structural parameters in the treatment group as compared with the control group. 12-month data from the IMPACT-DCM clinical has been accepted for presentation at the Heart Failure Society of America meeting to be held in September 2011.

#### Catheter Trial Program — DCM

In November 2009, the FDA activated our second IND in DCM to allow for the evaluation of our therapy delivered by a percutaneous direct catheter injection as opposed to surgically. The Catheter-DCM clinical trial is designed to explore catheter-based delivery of ixmyelocel-T to treat DCM patients. This multi-center, randomized, controlled, prospective, open-label, Phase 2 study enrolled approximately 11 patients with ischemic DCM and 10 patients with non-ischemic DCM at clinical sites across the United States. Participants met the same criteria as stated above for the IMPACT-DCM surgical trial. The first patient was enrolled into the trial in April 2010 and enrollment concluded in December 2010 with 21 patients enrolled. We expect to report six-month results from the Catheter-DCM Phase 2 trial in the third quarter of 2011.

### Results of Operations

Research and development expenses increased to $5,304,000 for the quarter ended June 30, 2011 from $3,619,000 for the quarter ended June 30, 2010. For the six months ended June 30, 2011, research and development expense increased to $9,676,000 from $6,464,000 during the same period a year ago. The increases are due to advanced preparation related to the Phase 3 clinical program for ixmyelocel-T, including increased employee costs, clinical site identification and set-up, as well as regulatory expenses. These amounts include non-cash stock-based compensation expense of $674,000 for the quarter ended June 30, 2011, compared to expense of $149,000 for the quarter ended June 30, 2010. For the six months ended June 30, 2011, non-cash stock-based compensation expense increased to $1,035,000 from $124,000 for the same period a year ago. The increases in stock-based compensation expense are due primarily to an increase in the number of stock options granted and an increase in the fair value per stock option driven by the increase in our stock price. Additionally, 2010 was impacted by the reversal of expense for certain non-vested stock options forfeited in excess of our assumed forfeiture rate.

Our major ongoing research and development programs are focused on the clinical development of ixmyelocel-T for treatment of severe, chronic cardiovascular diseases. The following table summarizes the approximate allocation of cost for our research and development projects (*in thousands):*

|  | Quarter Ended June 30, 2010 | 2011 | Six Months Ended June 30, 2010 | 2011 |
| --- | ---: | ---: | ---: | ---: |
| Critical Limb Ischemia | $1,533 | $4,152 | $2,708 | $6,505 |
| Dilated Cardiomyopathy | 2,060 | 1,147 | 3,696 | 3,145 |
| Other | 26 | 5 | 60 | 26 |
| Total research and development expenses | $3,619 | $5,304 | $6,464 | $9,676 |

Selling, general and administrative expenses increased to $2,203,000 for the quarter ended June 30, 2011 from $1,521,000 for the quarter ended June 30, 2010 due an increase in non-cash stock-based compensation and consulting costs. For the six-months ended June 30, 2011, selling, general and administrative expenses increased to $4,098,000 from $2,939,000 during the same period a year ago due to expenses associated with the previously announced restatement of the Company’s historical financial statements, as well as an increase in non-cash stock-based compensation and consulting costs. Non-cash stock-based compensation expense included in selling, general and administrative expenses increased to $558,000 for the quarter ended June 30, 2011 from $135,000 for the quarter ended June 30, 2010. For the six months ended June 30, 2011, non-cash stock-based compensation expense increased to $813,000 from $236,000 for the same period a year ago. The increases in stock-based compensation expense are due primarily to an increase in the number of stock options granted and an increase in the fair value per stock option driven by the increase in our stock price. Additionally, 2010 was impacted by the reversal of expense for certain non-vested stock options forfeited in excess of our assumed forfeiture rate

The income (expense) related to the non-cash change in fair value of warrants was ($2,465,000) for the quarter ended June 30, 2011 compared to $1,348,000 for the quarter ended June 30, 2010. For the six months ended June 30, 2011, the non-cash change in the fair value of warrants was ($1,210,000) compared to $2,907,000 for the same period a year ago. The fluctuation is due primarily to changes in the fair value of our common stock and the issuance of additional warrants in December 2010. Fluctuations in the fair value of warrants in future periods could result in significant non-cash adjustments to the condensed consolidated financial statements, however any income or expense recorded will not impact our cash and cash equivalents, operating expenses or cash flows.

Our net loss was $9,957,000, or $0.26 per share, for the quarter ended June 30, 2011 compared to $3,767,000, or $0.13 per share, for the quarter ended June 30, 2010. For the six months ended June 30, 2011, our net loss was $14,945,000, or $0.39 per share, compared to $6,446,000, or $0.23 per share, for the same period a year ago. The increases in net loss are primarily due to the non-cash change in the fair value of warrants, increases in research and development expenses, and the increase in selling, general and administrative expenses as described above. The per share comparisons were also impacted by the issuance of 10,000,000 shares of common stock in December 2010.

### Liquidity and Capital Resources

We are currently focused on utilizing our technology to produce patient specific cell-based therapies for use in severe chronic ischemic cardiovascular diseases. At such time as we satisfy applicable regulatory approval requirements, we expect the sales of our cell-based therapies to constitute nearly all of our product sales revenues.

We do not expect to generate positive cash flows from our consolidated operations for at least the next several years and then only if we achieve significant product sales. Until that time, we expect that our revenue sources from our current activities will consist of only minor sales of our cell products and manufacturing supplies to our academic collaborators, grant revenue, research funding and potential licensing fees or other financial support from potential future corporate collaborators.

We expect that we will need to raise significant additional funds or pursue strategic transactions or other strategic alternatives in order to complete our product development programs, complete clinical trials needed to market our products, and commercialize our products. To date, we have financed our operations primarily through public and private sales of our equity securities, and we expect to continue to seek to obtain the required capital in a similar manner. As a development stage company, we have never been profitable and do not anticipate having net income unless significant product sales commence. With respect to our current activities, this is not likely to occur until we obtain significant additional funding, complete the required clinical trials for regulatory approvals, and receive the necessary approvals to market our products. Through June 30, 2011, we had accumulated a net loss of $236,157,000. We cannot provide any assurance that we will be able to achieve profitability on a sustained basis, if at all, obtain the required funding, obtain the required regulatory approvals, or complete additional corporate partnering or acquisition transactions.

We have financed our operations since inception primarily through public and private sales of our equity securities, and, to a lesser degree, through grant funding, payments received under research agreements and collaborations, interest earned on cash, cash equivalents, and short-term investments, stock option and warrant exercises and funding under equipment leasing agreements. These financing sources have generally allowed us to maintain adequate levels of cash and other liquid investments.

Our cash and cash equivalents totaled $18,521,000 at June 30, 2011, a decrease of $12,727,000 from December 31, 2010. During the six months ended June 30, 2011, the primary uses of cash and cash equivalents included $12,208,000 for our operations and working capital requirements, and $412,000 in capital expenditures. Our cash and cash equivalents included money market securities with maturities of three months or less.

On June 16, 2011, the Company entered into an At the Market Sales Agreement (ATM) with McNicoll, Lewis & Vlak LLC (MLV), pursuant to which the Company may sell shares of its common stock through MLV, as sales agent, in registered transactions from its shelf registration statement filed in November 2010, for aggregate proceeds of up to $20,300,000. Shares of common stock sold under the ATM are to be sold at market prices. The Company will pay up to 3% of the gross proceeds to MLV as a commission. As of June 30, 2011, the Company had not sold any shares under the ATM.

Our future cash requirements will depend on many factors, including continued scientific progress in our research and development programs, the scope and results of clinical trials, the time and costs involved in obtaining regulatory approvals, the costs involved in filing, prosecuting and enforcing patents, competing technological and market developments, costs of possible acquisition or development of complementary business activities and the cost of product commercialization. We do not expect to generate positive cash flows from operations for at least the next several years due to the expected spending for research and development programs and the cost of commercializing our product candidates. We intend to seek additional funding through research and development agreements or grants, distribution and marketing agreements and through public or private debt or equity financing transactions. Successful future operations are subject to several technical and risk factors, including our continued ability to obtain future funding, satisfactory product development, obtaining regulatory approval and market acceptance for our products.

We believe that we will have adequate liquidity to finance our operations, including development of our products and product candidates, via our cash and cash equivalents on hand as of June 30, 2011 until at least December 31, 2011. While our budgeted cash usage and operating plan for 2011 does not currently contemplate taking additional actions to reduce the use of cash over the next six months, we could, if necessary, delay or forego certain budgeted discretionary expenditures such as anticipated hiring plans or certain non-critical research and development expenditures, as well as slow down or delay certain clinical trial activity (without jeopardizing our Phase 3 clinical trial of ixmyelocel-T for CLI) such that we will have sufficient cash on hand until at least December 31, 2011. We could also sell shares through the ATM in order to raise additional capital. Depending on the level of usage of the ATM, we will need to raise additional capital by early to mid-2012 in order to fund the phase 3 clinical trial of ixmyelocel-T for CLI. On a longer term basis, additional capital will be needed to complete our product development programs, complete clinical trials needed to market our products and commercialize these products. We cannot be certain that such funding will be available on favorable terms, if at all. Some of the factors that will impact our ability to raise additional capital and our overall success include: the rate and degree of progress for our product development, the rate of regulatory approval to proceed with clinical trial programs, the level of success achieved in clinical trials, the requirements for marketing authorization from regulatory bodies in the United States and other countries, the liquidity and market volatility of our equity securities, regulatory and manufacturing requirements and uncertainties, technological developments by competitors, and other factors. If we cannot raise such funds, we may not be able to develop or enhance products, take advantage of future opportunities, or respond to competitive pressures or unanticipated requirements, which would likely have a material adverse impact on our business, financial condition and results of operations.

### Off-Balance Sheet Arrangements

At June 30, 2011, we were not party to any off-balance sheet arrangements.

### Forward-Looking Statements

This report, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “estimates,” “plans,” “projects,” “trends,” “opportunity,” “comfortable,” “current,” “intention,” “position,” “assume,” “potential,” “outlook,” “remain,” “continue,” “maintain,” “sustain,” “seek,” “achieve,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. The factors described in Part I, Item 1A, “Risk Factors,” in our Transition Report on Form 10-KT for the six months ended December 31, 2010, among others, could have a material adverse effect upon our business, results of operations and financial conditions.

Because the factors referred to in the preceding paragraph could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements we make, you should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These forward-looking statements include statements regarding:

- potential strategic collaborations with others;
- future capital needs and financing sources;
- adequacy of existing capital to support operations for a specified time;
- product development and marketing plan;
- features and successes of our cellular therapies;
- manufacturing and facility capabilities;
- clinical trial plans and anticipated results;
- anticipation of future losses;
- commercialization plans; and
- revenue expectations and operating results.

## Controls and procedures

As filed, 1,674 characters.

#### Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2011. The term “disclosure controls and procedures” is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on their evaluation, our management, including our Chief Executive Office and Chief Financial Officer, concluded that our disclosure controls and procedures were effective.

#### Changes in Internal Control Over Financial Reporting

During the quarter ended June 30, 2011, we completed the remediation of the material weakness related to accounting for warrants, including development of a control that requires a more robust review of warrant agreements, if warrant agreements are entered into in the future. There have been no other changes in the Company’s internal control over financial reporting during the quarter ended June 30, 2011 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

#### Remediation of Material Weakness

During the quarter ended June 30, 2011, we completed the remediation of the material weakness related to accounting for warrants. In addition to the development of the control noted above, the remediation efforts also included the hiring of new accounting and finance personnel over the last year that successfully revisited the original accounting assessment for each of the historical warrants and ensured that the appropriate accounting treatment of the warrants was reflected in the current and prior periods.

## Risk factors

As filed, 363 characters.

Information regarding risk factors of the Company is set forth in Item 1A, “Risk Factors” in the Company’s Transition Report on Form 10-K for the six month period ended December 31, 2010. There have been no material changes in our risk factors from those disclosed in the Company’s Transition Report on Form 10-KT for the six month period ended December 31, 2010.

Filed Aug 15, 2011.
Source: SEC EDGAR, the filing index for accession 0001104659-11-046981. Last ingested by Listed: Nov 14, 2026, 12:33 ET. No prices; not investment advice.
